(MedPage Today) — Prescribing GLP-1 receptor agonists to children ages 8 to 11 years with obesity surged 310-fold since 2019, despite a lack of FDA approval in kids under 12, a large cross-sectional analysis showed.
Among over 3.5 million children…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
